Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00659945 · ClinicalTrials.gov registry record · Phase 4
Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery
A Phase 4 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT00659945 is a Phase 4 study that has completed, run by University of Pittsburgh. The registered enrollment target is 150 participants.
The verdict
NCT00659945, a Phase 4 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
Hypothesis: Aprepitant plus ondansetron is more effective than ondansetron plus placebo for prevention of postoperative emesis in patients at moderate-to-high risk for PONV for up to 48 hours after surgery. Specific Aim: To determine the incidence of PONV during the first 48 hours after surgery; in patients who have received aprepitant plus ondansetron versus ondansetron plus placebo for up to 48 hours after surgery.
Interventions
- DRUG Aprepitant plus Ondansetron
- DRUG Ondansetron plus placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00659945
The ClinicalTrials.gov registry entry for NCT00659945 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aprepitant plus Ondansetron is the first listed.
NCT00659945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00659945 about?
NCT00659945 is a clinical study titled "Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery". Hypothesis: Aprepitant plus ondansetron is more effective than ondansetron plus placebo for prevention of postoperative emesis in patients at moderate-to-high risk for PONV for up to 48 hours after surgery. Specific Aim: To determine the incidence of PONV during the first 48 hours after surgery; in...
What is the current status of trial NCT00659945?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2008-06. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00659945?
The interventions under investigation include: Aprepitant plus Ondansetron (DRUG), Ondansetron plus placebo (DRUG).
Who is sponsoring clinical trial NCT00659945?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.